Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-Pd-L1 Immune Checkpoint Inhibitor

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2020.00420
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Systemic Immunotherapy of Superficial Mouse Bladder Cancer With Avelumab (MSB0010718C), an Anti-Pd-L1 Immune Checkpoint Inhibitor

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

The Expression of PD-L1 in Salivary Gland Carcinomas

Scientific Reports
Multidisciplinary
2019English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer
Oncology
2020English

Analysis of Blimp-1 and PD-1/PD-L1 Immune Checkpoint in an Autoimmune Thyroiditis Animal Model

International Journal of Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2020English

Localization of Salivary Proteins in Granules of Human Parotid and Submandibular Acinar Cells

Critical Reviews in Oral Biology & Medicine
1993English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy